New Anti-Chemokine Oral Drug XC8 in the Treatment of Asthma Patients with Poor Response to Corticosteroids: Results of a Phase 2A Randomized Controlled Clinical Trial

New Anti-Chemokine Oral Drug XC8 in the Treatment of Asthma Patients with Poor Response to Corticosteroids: Results of a Phase 2A Randomized Controlled Clinical Trial

Abstract Introduction A significant number of patients with moderate asthma remain symptomatic despite treatment with inhaled corticosteroids (ICS). These patients do not yet meet the criteria for oral corticosteroids (OCS) and monoclonal antibodies. The new anti-chemokine oral drug XC8 could repres...

Full description

Bibliographic Details
Main Authors: Julia Romanova, Elena Chikina, Anastasia Rydlovskaya, Wolfgang Pohl, Andreas Renner, Alexey Zeifman, Alexander Chuchalin, Vladimir Nebolsin
Format: Article
Language:English
Published: Adis, Springer Healthcare 2020-10-01
Series:Pulmonary Therapy
Subjects:
Asthma
Chemokine
Corticosteroid resistance
Eosinophils
Interferon-gamma
XC8
Online Access:https://doi.org/10.1007/s41030-020-00134-5

Internet

https://doi.org/10.1007/s41030-020-00134-5

Similar Items